21 CFR 212 PET Drug cGMP Readiness

21 CFR 212 PET Drug cGMP Readiness starts with a connected manufacturing record, not a collection of completed forms. The practical question is whether a reviewer can follow the materials used, the instructions executed, the equipment involved, the laboratory evidence, the release decision, and the receiving facilities without reconstructing missing connections. This guide follows that path across production and quality control. Legal requirements are identified by their regulatory sections; paragraphs labeled Practice describe implementation suggestions, not additional law or FDA guidance.

Law — §212.2 establishes minimum CGMP requirements for PET drugs intended for human use. Under §212.5(a), Part 212 applies only to PET drug production, quality assurance, holding, and distribution; human drugs outside the PET definition must be manufactured under Parts 210 and 211. Section 212.5(b) provides two CGMP routes for the specified IND and RDRC PET drugs: compliance with Part 212, or production in accordance with the specifically incorporated May 1, 2009 version of USP Chapter 823, USP 32/NF 27, pages 365–369. It does not require those drugs to use the USP route. No individual USP chapter requirements are described here.

Practice — Record the product and manufacturing route before building the readiness package. Keep separate assessments for medical-use permissions, radiation protection, transport permissions, and EU compliance: this manufacturing guide does not establish any of them. For a shorter orientation, use the Part 212 overview.

Law — §212.10 requires sufficient personnel with the education, background, training, and experience needed for their assigned functions, together with adequate facilities, equipment, and other resources. Section 212.20 requires oversight of production, examination and approval or rejection of materials and finished dosage forms, and written quality assurance procedures. Readiness therefore involves both the people available to do the work and the quality decisions made about that work.

Law — Under §212.20(c), initial specifications, methods, processes, and procedures, and proposed changes to them, must be approved or rejected before implementation. A change must be demonstrated not to adversely affect PET drug identity, strength, quality, or purity. Section 212.20(d) also requires production-record review for errors, determination of the need for investigation when errors or specification failures occur, investigations when necessary, and appropriate corrective actions.

Practice — Build a responsibility list around actual decisions rather than job titles alone. Identify who can release incoming materials, approve a changed method, review a batch, authorize final release, investigate an abnormal result, and contact receiving facilities. Add a named coverage arrangement for absences and out-of-hours follow-up. A telephone number without a person responsible for answering and acting is a weak handoff, particularly when a result arrives after dispatch.

Practice — Training evidence is most useful when it connects a person to the current task and procedure: operating a particular synthesis system, preparing a test solution, reviewing an instrument record, or carrying out a notification. In an internal rehearsal, ask the assigned person to explain one recent decision and retrieve its supporting record. Use any difficulty to improve the procedure or training; do not treat attendance at a general CGMP session as the whole demonstration of readiness.

Law — §212.30 requires facilities adequate for orderly handling and prevention of mix-ups and contamination. Equipment procedures must ensure that equipment capable of affecting product quality or producing erroneous results is clean, suitable, properly installed and maintained, and capable of repeatedly producing valid results. Activities under those procedures must be documented. Product-contact surfaces must not be reactive, additive, or absorptive in a way that alters PET drug quality.

Practice — Walk the physical route before reviewing the paperwork. Follow a precursor from receipt to storage, a container from accepted stock to use, and a sample from production to the laboratory. Look for points where two lots, two batches, or accepted and unaccepted items could become confused. Then compare the route with the written procedure. The useful output is a specific correction—such as a clearer storage designation or sample handoff—not a generic statement that the area was inspected.

Practice — For each major production or analytical instrument, keep its identity consistent across operating records, maintenance records, test data, and batch records. Following a repair or configuration change, document the assessment of suitability for the next intended use and any linked procedure or method changes. A maintenance entry saying only that work was completed may not explain whether the affected function was checked. This guide does not prescribe a universal room classification, monitoring frequency, qualification cycle, or aseptic simulation schedule; those details need a justified, product- and operation-specific basis.

Law — §212.40 requires written procedures for receipt, login, identification, storage, handling, testing, acceptance, and rejection, together with appropriate written specifications. Each incoming lot must be uniquely identified and tested or examined against those specifications, sourced from a reliable supplier, and designated quarantined, accepted, or rejected. A lot cannot be used if it fails specifications, including an applicable expiration date, or has not received material release. Material release is the responsible person's authoritative decision permitting use of the material in production, as defined in §212.1.

Law — Handling and storage must prevent contamination, mix-ups, and deterioration and maintain suitability. The record for each shipment of each lot must include shipment identity and quantity, supplier name and lot number, receipt date, test results, disposition of rejected material, and an expiration date where applicable. These obligations remain relevant whichever component-testing route applies.

Practice — Make the testing-route decision visible in the material specification or linked assessment. A certificate filed in a supplier folder is not, by itself, an explanation of why a particular identity-testing route applies. During a batch rehearsal, choose one component and trace it backward to receipt and forward to every relevant production entry. Check that the quantity issued belonged to an accepted, unexpired lot at the time of use—not merely that the supplier was generally approved.

Law — §212.50 requires adequate production and process controls, written procedures controlling key process parameters, and justification of deviations. Master production and control records document the production instructions; a unique batch production and control record is required each time a batch is produced. The following comparison separates the rule's planned instructions from its execution evidence.

Law — Immediately before use, the production area and all equipment in it must be checked for cleanliness and suitability, and those checks recorded. In-process materials must remain controlled until required tests or other verification activities are completed, or necessary approvals are received and documented. A completed master template does not replace these batch-specific controls.

Law — Process verification under §212.50(f)(2) is conditional, not a blanket requirement to run three validation batches. It is not required as described there when each entire batch receives full finished-product testing ensuring all specifications are met. When an entire batch is not fully verified through finished-product testing, or only the initial sub-batch in a series is tested, the producer must demonstrate reproducibility and capability to meet predetermined acceptance criteria. Documentation includes verification dates and signatures, monitoring and control methods and data, and the major equipment qualified.

Practice — Reconcile the master record with one completed batch line by line. Check component codes, permitted quantity variations, equipment identities, and critical timestamps. Treat an unexplained yield departure as a question requiring its own documented assessment; do not quietly replace an action limit with a different acceptance criterion. When a process changes, review the testing coverage and verification rationale as well as the operating instruction. The aim is a defensible record of the actual process, not a fixed batch count adopted without explanation.

Law — §212.60 requires written test and result-documentation procedures, appropriate sampling and testing procedures, and methods sufficiently sensitive, specific, accurate, and reproducible for their intended use. Reagents, solutions, and supplies must be controlled; prepared solutions must carry identity and expiration labeling. Testing equipment must be suitable and capable of valid results, with documented routine calibration, inspection, checking, and maintenance under written procedures.

Law — The written stability program must assess the product's stability characteristics using reliable, meaningful, specific methods. Samples must represent their source lot or batch and be stored under suitable conditions. Results must be documented and used to determine appropriate storage conditions and expiration dates and times for each product. Neither this requirement nor the laboratory equipment provisions establish a universal shelf life or one calibration interval for every instrument.

Practice — Select a reported result and independently reconstruct its calculation using the recorded inputs. Check the units and any reference time used, then compare the reconstructed value with the reported result and specification. If a transcription or calculation changes, preserve an understandable explanation of what changed and why. Separately, review whether a production, formulation, container, or storage change affects the relevance of existing stability evidence. Keep that assessment distinct from simply observing that today's batch passed its immediate tests.

Law — §212.70(a) requires product specifications covering identity, strength, quality, purity, and, if appropriate, sterility and pyrogens. Before final release, §212.70(c) requires an appropriate laboratory determination of conformance, except for sterility, for each batch and each sub-batch when production uses sub-batches. Except for the narrow conditional-final-release route, associated laboratory data and documentation must be reviewed and demonstrate conformance except for sterility, and a designated qualified individual must authorize final release by dated signature under §212.70(d).

Practice — Use clearly defined working statuses such as available and conforming, pending, and failed. These are site recordkeeping terms, not substitutes for the regulation's decisions. A result being available says nothing by itself about conformance; a reviewer still needs the criterion and supporting data. Likewise, an acceptable result set does not sign the release record. Make the final authorization easy to distinguish from an analyst's signature or an earlier production check.

Law — Under §212.70(e), sterility testing need not be completed before final release but must start within 30 hours after production is completed. The 30-hour period may be exceeded because of a weekend or holiday. If a sample is held longer, the producer must demonstrate that the longer hold does not adversely affect it and that results will be equivalent to those obtained had testing started within 30 hours. Samples must come from individual batches and must not be pooled.

Law — A sterility-criterion failure requires immediate notification of all facilities that received the product, communication of the test results and appropriate recommendations, and documentation of the notification. After the investigation is completed, all those facilities must also receive its findings. Do not wait for the completed investigation before making the initial failure notification.

Practice — Maintain two different follow-up lists: one for sterility starts and results, another for any equipment-malfunction event. Record the responsible person, relevant timestamps, receiving facilities, and outstanding action. For a weekend hold, connect the actual sample conditions to the equivalence demonstration rather than recording only that the laboratory was closed. Test the notification arrangement during an internal rehearsal: can the responsible person identify every recipient and document what was communicated without waiting for someone else to reconstruct distribution?

Law — §212.71 requires rejection of a nonconforming batch, procedures to identify and segregate it against mix-ups, and investigation of the causes. The investigation must consider processes, operations, records, complaints, and other relevant information. Its results and the rejected product's disposition must be documented, and identified problems corrected to prevent recurrence. Reprocessing is allowed only where appropriate; material failing acceptance criteria must be reprocessed under procedures stated in the approved application, and the finished product must conform except for sterility before final release.

Law — §212.100 separately requires written procedures for complaints about quality, purity, or possible adverse reactions. Complaints involving possible specification failure require designated-person review and investigation of the cause. Complaint records include product name and strength, batch number, complainant, receipt date, nature, response, investigation findings, and follow-up. A PET drug returned because of a complaint—or for any other reason—may not be reprocessed and must be destroyed in accordance with applicable Federal and State law.

Practice — Keep three decisions visible: the batch disposition, the investigation conclusion, and any permitted subsequent processing decision. A plausible explanation does not erase a failed specification or turn a returned finished product into eligible reprocessing material. Link complaints to the manufacturing and distribution record so that an investigation can examine the actual batch, not only a summary of the caller's concern. When closing corrective work, record what was changed and how its intended effect will be checked.

Practice exercise — Fictional batch EX-01 records completion of production at 08:00 on Day 1. The batch has no sub-batches. Its container ledger records 24 empty vials received, two rejected for damage, and 22 given material release before use. Five accepted vials are issued: one product vial, one reserve-sample vial, one sterility-sample vial, and two analytical-sample vials. All volume allocations below are recorded against the 08:00 production reference point; none is a radioactivity measurement.

At 08:20, some required nonsterility results are available and conform to the fictional written specifications, but another required result is pending during ordinary analysis. There is no analytical-equipment malfunction. The record therefore does not support final release at that point, and §212.70(f) is not an available shortcut. At 08:40 the remaining result becomes available and conforms. For this exercise, assume the required associated-data review is completed and supports the designated qualified individual's dated final-release authorization at 08:55. Dispatch to the single recorded receiving facility occurs at 09:10.

Sterility testing begins at the time shown in the table, but a sterility-criterion failure is reported at 10:00 on Day 3. The product is no longer merely awaiting that result: the failure activates immediate recipient notification, documentation, and investigation follow-up under §212.70(e). The completed investigation's findings must also reach the receiving facility. The earlier quantity reconciliation remains arithmetically correct; it never proved sterility or safety. A useful trainee response identifies both facts without trying to make the ledger balance cancel the failed result.

Law — §212.80 requires suitable labeling and packaging to protect the product during established shipping, distribution, handling, and use conditions. Labels must remain legible and affixed, every label's information must also appear in the batch record, and operations must prevent labeling and product mix-ups. Section 212.90 requires written distribution controls ensuring that the chosen shipping method does not adversely affect identity, purity, or quality.

Practice — At the handoff, compare the labeled product, batch identity, destination, shipment record, and recorded authorization. Keep recipient details available to the person responsible for later sterility or reserve-sample notifications. If one batch goes to several facilities, make that distribution visible as several recipient connections rather than a single dispatch summary. These checks address the manufacturing evidence chain; they are not a transport qualification protocol or a determination that separate transport permissions have been satisfied.

Law — §212.110 permits records at the production facility or another location reasonably accessible to responsible facility officials and designated FDA inspectors. All records must be legible, protected against deterioration or loss, and readily available for FDA review and copying. Records and documentation referenced in Part 212 must be retained for at least one year from final release, including conditional final release—not simply one year from manufacture or document creation.

Practice — Use the release date as the starting point when implementing that minimum, and keep links between shared records and the batches they support visible before disposal decisions. Include externally held laboratory or maintenance records in the retrieval rehearsal. A reference to another location is useful only if the responsible team can obtain the relevant evidence in a usable form. Do not assume that a summary report replaces the underlying records required by the applicable section.

1. Choose a completed batch and retrieve its master record, material receipts and releases, pre-use checks, execution entries, and laboratory records.
2. Reconstruct the critical timeline, including sample collection, testing, data review, authorization, shipment, and sterility-test start.
3. Follow one discrepancy or quality event through disposition, investigation, corrective action, and any receiving-facility notification.
4. Check one change record against the equipment, method, or production instruction actually used.
5. Assign owners to missing connections and repeat the retrieval exercise after corrections are completed.

Practice — Judge readiness by whether the evidence explains the decisions, including inconvenient results and outstanding follow-up. This is an internal preparation method, not a prediction of an inspection outcome. A coherent record should allow another qualified person to understand what was done, why the batch received its disposition, and what obligations continued after dispatch.